Application of PET/MRI in Gynecologic Malignancies

Ebrahimi, Sheida; Lundström, Elin; Batasin, Summer J.; Hedlund, Elisabeth; Stålberg, Karin; Ehman, Eric C.; Sheth, Vipul R.; Iranpour, Negaur; Loubrie, Stephane; Schlein, Alexandra; Rakow-Penner, Rebecca

doi:10.3390/cancers16081478

Cited by 2 publications

(1 citation statement)

References 137 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the integration of PET and MR imaging technologies enhances overall diagnostic precision (Mayerhoefer et al, 2020;Pichler et al, 2008). MR imaging is renowned for its exceptional soft tissue contrast, which, when combined with the functional imaging capabilities of PET, enables a more comprehensive evaluation of pelvic lesions (Ebrahimi et al, 2024). Consequently, PSMA-PET offers a more precise visualization of the pelvic region, facilitating well-informed clinical decisions.…”

Section: Discussionmentioning

confidence: 99%

18F-PSMA-1007 PET/MR for Early Detection of Biochemical Recurrence of Prostate Cancer in Very Low (≤ 0.5 ng/mL) Prostate-Specific Antigen Levels

Lin,

Wei,

Shen

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose To evaluate the diagnostic efficacy of 18F-PSMA-1007 PET/MR (PSMA-PET) in detecting biochemical recurrence (BCR) of prostate cancer (PCa) at very low (≤ 0.5 ng/mL) prostate-specific antigen (PSA) levels. Methods We recruited 157 PCa patients with BCR post-radical prostatectomy or radiation therapy between May 2021 and January 2023. Among them, 52 patients with PSA ≤ 0.5 ng/mL underwent PSMA-PET imaging. The imaging protocol included multiparametric MRI (mpMRI) and PET data analysis, with lesion classification based on PSMA-RADS version 1.0. Results The PSMA-PET imaging demonstrated a 63.5% detection rate for recurrent PCa in patients with low PSA levels. PSMA-PET detected 34 local recurrent lesions, 12 metastatic lymph nodes, and 4 skeletal metastases. Follow-up imaging reclassified initially equivocal lesions, increasing the detection rate to 73.1%. Outcomes from PSMA-PET imaging significantly influenced personalized treatment strategies, impacting clinical decisions for 17% of the participants in our investigation. Conclusion PSMA-PET significantly enhances the detection of recurrent PCa at low PSA levels, providing precise localization and aiding in personalized treatment strategies. Further research is essential to optimize its clinical application and validate long-term efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

18F-PSMA-1007 PET/MR for Early Detection of Biochemical Recurrence of Prostate Cancer in Very Low (≤ 0.5 ng/mL) Prostate-Specific Antigen Levels

Lin,

Wei,

Shen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

The Diagnostic and Prognostic Value of 18F-FDG PET/MR in Hypopharyngeal Cancer

Fan,

Shen,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective To evaluate the diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MR) in the preoperative staging of hypopharyngeal cancer (HPC), compare it with conventional enhanced computed tomography (CT) and MR, and further explore the prognostic value of its metabolic and diffusion metrics for HPC. Methods This retrospective study included 33 patients with pathologically confirmed HPC. All patients underwent preoperative 18F-FDG PET/MR, CT, and MR examination. The staging performance of the three modalities was evaluated using pathological staging as a reference. Additionally, metabolic indicators and diffusion-related parameters from PET/MR were collected to investigate their impact on larynx preservation and survival. Results PET/MR demonstrated accuracies of 90.9% and 71.4% in the preoperative T and N staging, respectively, significantly higher than those of CT (54.5%, P = 0.001; 42.9%, P = 0.021) and MR (66.7%, P = 0.016; 42.9%, P = 0.021). Significant differences were observed in the maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), minimum apparent diffusion coefficient (ADCmin), and mean ADC (ADCmean) across different T stages, and in SUVmax, mean SUV (SUVmean), total lesion glycolysis (TLG), and MTV across different N stages. ADCmin and ADCmean showed good predictive capability for larynx preservation, with AUCs of 0.857 and 0.920 (P < 0.05), respectively. In survival analysis, high ADCmin (P < 0.0001) and high ADCmean (P = 0.0011) were significantly associated with better survival, with AUCs of 0.815 and 0.866 (P < 0.05), respectively. Conclusion In HPC, 18F-FDG PET/MR imaging significantly surpasses CT and MR in preoperative diagnostic staging. Its diffusion-related parameters have substantial prognostic value, with high ADC values associated with larynx preservation and favorable survival, serving as prognostic indicators for HPC.

show abstract

Application of PET/MRI in Gynecologic Malignancies

Cited by 2 publications

References 137 publications

18F-PSMA-1007 PET/MR for Early Detection of Biochemical Recurrence of Prostate Cancer in Very Low (≤ 0.5 ng/mL) Prostate-Specific Antigen Levels

18F-PSMA-1007 PET/MR for Early Detection of Biochemical Recurrence of Prostate Cancer in Very Low (≤ 0.5 ng/mL) Prostate-Specific Antigen Levels

The Diagnostic and Prognostic Value of 18F-FDG PET/MR in Hypopharyngeal Cancer

Contact Info

Product

Resources

About